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Abstract
Background: Viral promoters are used in mammalian expression vectors because they generally
have strong activity in a wide variety of cells of differing tissues and species.
Methods: The utility of the BLV LTR/promoter (BLVp) for use in mammalian expression vectors
was investigated through direct comparison to the CMV promoter (CMVp). Promoter activity was
measured using luciferase assays of cell lines from different tissues and species stably transduced
with BLVp or CMVp driven luciferase vectors including D17, FLK, BL3.1 and primary bovine B cells.
Cells were also modified through the addition of BLV Tax expression vectors and/or BLV infection
as well as treatment with trichostatin A (TSA).
Results: Results indicate the BLV promoter, while having low basal activity compared to the CMV
promoter, can be induced to high-levels of activity similar to the CMV promoter in all cells tested.
Tax or BLV infection specifically enhanced BLVp activity with no effect on CMVp activity. In
contrast, the non-specific activator, TSA, enhanced both BLVp and CMVp activity.
Conclusion: Based on these data, we conclude the BLV promoter could be very useful for
transgene expression in mammalian expression vectors.
Background
Viral promoters are commonly used as regulatory ele-
ments in gene therapy vectors due to their strong activity
in various cell lines in vitro. Probably the most widely
used promoter in mammalian expression systems is the
human cytomegalovirus immediate-early gene (CMV)
promoter. The CMV promoter induces high-level consti-
tutive expression in a variety of mammalian cell lines [1].
In many gene therapy applications, however, an inducible
or cell specific promoter would be more appropriate. A
regulated transgene expression system in mammalian
cells is preferable for effective and safe gene therapy and
for the study of gene function in cell biology. The most
important features of an inducible promoter would be 1)
low basal expression levels; 2) high induced expression;
and 3) inducer-specific, modulated expression [2]. Our
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need for a mammalian expression vector promoter for
preventative gene therapy that would be induced by
bovine leukemia virus (BLV) infection or BLV Tax protein
expression led us to investigate the use of the BLV pro-
moter for gene therapy.
The U3 region of the BLV promoter, located in the 5' long
terminal repeat (LTR), contains several important cis-act-
ing elements in addition to the CAAT box, TATA box, and
transcription start site [3,4]. The major regulatory ele-
ments are three copies of an imperfectly conserved 21-bp
sequence called the tax responsive element (TxRE). The
TxREs are essential for the promoter's responsiveness to
the Tax transactivator protein encoded by the 3' end of the
proviral genome [5]. These cis-elements contain motifs
resembling the cyclic AMP-responsive element (CRE) as
well as an E box sequence [6]. Tax does not bind directly
to the TxRE but interacts with cellular proteins that recog-
nize the CRE including the transcription factors CREB,
ATF-1, and ATF-2 [7-9]. The transcription factor AP4 can
potentially bind to the E box sequence and is important in
Tax activation [10]. There is a glucocorticoid responsive
element (GRE) that responds to dexamethasone in the
presence of glucocorticoid receptors and Tax [11]. A
nuclear factor κB (NFκB) binding site responds to phor-
bol 12-myristate 13-acetate (PMA) treatment [12].
Finally, there is a Tax transactivator independent site spe-
cific for the B cell transcription factors PU.1 and Spi-B
[13]. This PU.1/Spi-B binding site may be involved in the
B lymphocyte tropism of BLV.
We hypothesized that the BLV promoter could be used in
mammalian expression vectors for regulated high-level
gene expression. Our approach was to compare reporter
gene expression driven by either the BLV promoter or
CMV promoter in different cell types with or without BLV
infection or Tax induction. Our results demonstrate that
the BLV promoter can be induced to express the reporter
gene to levels as great as the constitutive CMV promoter.
Methods
Cell culture
All cells used in these studies were maintained in RPMI
1640 medium (Invitrogen) supplemented with 10% fetal
calf serum (FCS), 4.5% dextrose, 1 mM sodium pyruvate,
and antibiotic-antimycotic solution (100 µg/ml penicillin
G sodium, 100 µg/ml streptomycin sulfate, 0.25 µg/ml
amphotericin B). In addition, the following concentra-
tions of drugs were added for each selective media: Blasti-
cidin-S (Invivogen) 10 µg/ml; G418-sulfate (Alexis
Biochemical) 400 µg/ml. The following cell lines were
used: D17 [dog osteosarcoma; ATCC CCL-183; [14]], FLK
[sheep kidney; BLV expresser; [15]], BL3.1 [bovine B-lym-
phosarcoma; BLV expresser; ATCC CRL-2306; [16]]. Pri-
mary bovine B cells were supplemented with 10 ng/ml
each of recombinant human interleukin-4 and inter-
leukin-7 (Peprotech, Inc.), and gamma-irradiated (4,000
R) murine CD40L-expressing L cells (J558L; a gift from
Philip Griebel) as described elsewhere [17]. For the TSA
experiments, Trichostatin A (Sigma) was supplemented at
500 nM for 48 h. Cells were cultured at 37°C in a 5% CO2
humidified atmosphere. Viable cells were identified by
trypan blue dye exclusion, and cell number was counted
with a hemacytometer.
Primary bovine B cells were purified as follows. Peripheral
blood mononuclear cells (PBMC) were isolated from
heparinized cow blood through a ficoll density gradient as
previously described [18]. B cells were separated from the
PBMCs using the MiniMACS system following the manu-
facturer's (Miltenyi Biotec) protocol. Briefly, 1 × 107 cells
were stained for 15 min at 6° – 12°C with 10 µg/100 µl
total volume anti-IgM (PIG45A; VMRD, Inc.). After wash-
ing, 20 µl/100 µl total volume of MACS rat anti-mouse
IgG2a+b microbeads were mixed with the cells and incu-
bated for 15 min at 6° – 12°C. Cells were thoroughly
washed, and magnetically separated. These IgM+ cells
were considered primary B cells. Microfluorimetry using
anti-IgM (PIG45A; VMRD, Inc.) indicated 90% purity.
Stably transduced cell lines were generated after one week
in selective media. Primary B cells were analyzed after one
week in selective media since they began to die out after
two weeks in culture.
Vector construction
The plasmid pBLV913 (a gift from David Derse), coding
for an infectious molecular clone of BLV [5] was used as
the source for the BLV promoter and BLV Tax sequences.
Briefly, the BLV promoter from the U3 region of 3' LTR of
BLV was isolated from plasmid pBLV913 (Derse) as a 345
bp fragment (GenBank LOCUS BLVCG, ACCESSION
K02120 bp 8096 – 8440) and cloned in place of the CMV
promoter fragment into pLNCX (Clontech; Genebank
LOCUS SYNMMLPLN3 ACCESSION M28247 – CMV pro-
moter removed as Bam HI-Hind III fragment) to create the
vector pLNBlv. The pLNBlv and pLNCX retrovector plas-
mids were modified to place the Gateway Rfa cassette (1.7
kb; Invitrogen) downstream of the internal promoters
(BLV or CMV) in order to simplify further cloning, to cre-
ate retrovector plasmids pLNBlv-G or pLNC-G. For
enhanced protein expression, the WPRE element (from
plasmid BluescriptII SK+ WPRE-B11 (a gift from Tom
Hope–the same as bp 2717–3309 of Genbank Locus
OHVHEPBA ACCESSION J04514) was cloned down-
stream of the Gateway Rfa cassette with standard cloning
methods to create vectors pLNC-GW and pLNBlv-GW.
The source for firefly luciferase encoding sequence was
pGEM-luc (Promega). The luciferase coding sequence was
subcloned into pENTR1A (Invitrogen) to engineer the
Gateway entry vector pENTR1A/luc. The Luciferase geneGenetic Vaccines and Therapy 2004, 2:11 http://www.gvt-journal.com/content/2/1/11
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was recombined into pLNC-GW or pLNBlv-GW using LR
Clonase (Invitrogen) per manufacturer's instructions. The
promoter-less luciferase expression control vector
pLN[]W/luc was engineered by removing the BLV pro-
moter (Bam HI digest) from pLNBlv/luc. BLV Tax (Gen-
bank Locus AAF97920) was isolated by reverse
transcription PCR from FLK cells and subcloned into
pENTR1A (Invitrogen) to engineer the Gateway entry vec-
tor pENTR1A/Tax. The Tax gene was recombined into
pLBC-GW where the neomycin resistance gene of pLNC-
GW was replaced with the blasticidin resistance gene.
Throughout these studies we assayed expression vectors
with and without the WPRE. WPRE enhanced transgene
expression in all cell lines used, and in a promoter-inde-
pendent fashion (about 2-fold greater for BLVp and
CMVp in D17 cells). Subsequently, all data shown in this
report are only with vectors containing WPRE.
Cell transfection and transduction
Retrovirus-mediated gene transfer was accomplished
using the BD Retro-X System (BD Biosciences Clontech)
following the manufacturer's suggested protocol. Briefly,
100 mm × 20 mm tissue culture dishes (Falcon) were
seeded with the packaging cell line GP2-293 at 70–90%
confluency. Each dish of GP2-293 cells was co-transfected
with 5 µg each of retroviral vector and the envelope glyc-
oprotein expression vector pVSV-G using 15 µl/transfec-
tion of Lipofectamine 2000 (Invitrogen) cationic lipid
reagent for 3 h in a total volume of 5 ml medium/dish.
Subsequently, transfection medium was replaced with 10
ml growth medium, and the cells were incubated for 72 h.
Retrovirus-containing supernatant was then harvested
and passed through a 0.45 µm cellulose acetate filter, then
concentrated by ultracentrifugation at 50,000 × g for 30
min at 4°C. Supernatant was carefully poured off and
virus was resuspended in the residue (~200 µl) and frozen
(-70°C) for future use. Cells for transduction were plated
on 6-well tissue culture plates (Falcon) at 50% conflu-
ency. Concentrated retrovirus (titer unknown) along with
polybrene (8 µg/ml) were added to one ml/well cells (in
a 6-well plate) and incubated overnight. Transduction
medium was replaced with fresh growth medium, and the
following day cells were split into appropriate selective
medium. BLV was harvested from supernatant of FLK
cells, concentrated, and used to transduce cells in a similar
fashion.
Luciferase assay
Luciferase assays (Promega) were performed using a sin-
gle-tube luminometer (Pharmingen) to measure relative
light units (RLU) on a linear scale. Cells to be assayed
were counted using a hemacytometer, and 1 × 106 cells
were aliquoted to 1.5 ml microcentrifuge tubes. Then,
cells were pelleted at 300 × g for 10 min, washed once
with PBS, and lysed with 200 µl reporter lysis buffer
(Promega). Lysate was stored at -20°C until assayed.
Lysate was thawed and pelleted (300 × g for 10 min), and
luciferase was measured with the luminometer using 10 µl
lysate/50 µl reagent for 10 s. Linear range was under 1 ×
107 RLU.
Statistical analysis
Student's t-test was performed for statistical evaluation of
the results. Results are expressed as the arithmetic mean
with the variance of the mean (mean ± SE).
Results
The BLV promoter was engineered to drive reporter genes
Our studies utilized a commercially available retroviral
system with its standard CMV promoter (CMVp) or
replaced with the BLV promoter (BLVp). Figure 1 shows a
schematic of the BLV promoter used in these studies with
its unique regulatory elements. The luciferase reporter
gene was used to compare promoter expression strength
within different cell lines and treatments. The Woodchuck
Hepatitis Virus posttranscriptional regulatory element
(WPRE) was also incorporated to enhance transgene
expression within these retroviral vectors [19,20]. WPRE
has been reported to significantly stimulate expression of
transgenes in a promoter-independent fashion [19]. Ret-
roviral vectors were used because of the ease of stable cell
line establishment, and because of their prominent use in
transgenics and gene therapy. The commercially available
retroviral vector used in these studies contained the CMV
IE promoter for transgene expression. We modified this
retrovector for comparison studies replacing the CMV IE
promoter with the BLV promoter (see methods). Cells of
several different tissues and species were used in our
studies.
The BLV promoter can be as strong as the CMV promoter 
depending on the host cell
In contrast to the constitutive expression of the CMV pro-
moter, the BLV promoter has cis elements that are depend-
ent on BLV Tax for transgene expression [5,21,22]. We
hypothesized therefore that in a cell line such as D17, the
BLV promoter would have little or no activity compared to
the CMV promoter. Conversely, in a cell line expressing
the BLV Tax transactivator such as the BLV-producing FLK
cell line, the BLV promoter would have similar activity
compared to the CMV promoter. We tested this assump-
tion with luciferase as the transgene and found indeed,
BLV promoter activity was about 50-fold less than CMV
promoter activity in D17 cells but was about equal in FLK
cells (Fig. 2). As shown in Figure 1, the BLVp also has a cis
element that is B cell specific (PU.1/Spi-B). We therefore
compared the strengths of BLV and CMV promoters in pri-
mary B cells and a BLV infected B cell line hypothesizing
that BLVp expression would be comparable to CMVpGenetic Vaccines and Therapy 2004, 2:11 http://www.gvt-journal.com/content/2/1/11
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activity. BLVp activity was still less than CMVp activity in
primary B cells but by only about a 5-fold difference (Fig.
2). In the BLV infected BL3.1 cell line, BLVp activity was
approximately equal to CMVp activity, analogous to
results using the BLV infected FLK cell line. Thus, the BLV
promoter can be as strong as the CMV promoter within a
cell line under specific conditions e.g. BLV infection/Tax
expression.
BLV infection enhances BLV promoter expression but has 
no effect on the CMV promoter
Since BLV promoter activity was greater than CMV pro-
moter activity in the BLV infected FLK cell line but mini-
mal compared to CMV promoter activity in the non-BLV
infected D17 cell line, we set out to determine whether
BLV infection of D17 cells would enhance BLVp and/or
suppress CMVp expression. The dog derived D17 cell line
Schematic representation of BLV promoter used in comparison studies Figure 1
Schematic representation of BLV promoter used in comparison studies. The BLV promoter (BLVp) consisting of the U3 region 
of the 5'LTR of BLV includes the basic elements of transcription start site (+1), CAAT (nt -97/-92) and TATA (nt -43/-37) 
boxes as shown. Unique to the BLVp are the three imperfectly conserved 21 bp sequences known as the Tax Responsive Ele-
ments (TxRE). The numbers following the TxRE designation represent its position relative to the transcription start site. Each 
TxRE contains a consensus E box-binding motif overlapping an imperfect cyclic AMP responsive element motif (CRE/Ebox). 
Additionally, the BLVp contains a glucocorticoid responsive element (GRE), Nuclear Factor Kappa Binding motif (NFkB), and B 
cell specific PU.1 or Spi-B transactivator binding motif (PU.1/Spi-B). The transcription elements are not drawn to scale.
BLVp and CMVp activity comparison in D17, FLK, primary cow B cells, and BL3 Figure 2
BLVp and CMVp activity comparison in D17, FLK, primary cow B cells, and BL3.1. Relative light units (RLU) of luciferase activ-
ity driven by either the BLV promoter (BLVp) or CMV promoter (CMVp) of 1 × 106 stably transduced cells was measured dur-
ing a 10 s period. Bars represent the arithmetic mean and variance of 10 experiments. *P < 0.05; **P < 0.001 determined by t-
test.
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can be infected with BLV albeit not very efficiently [14].
D17 cells were infected with concentrated BLV from FLK
cells, then clonally selected for BLV expression using pol
RT-PCR and BLV reverse transcriptase assay of the super-
natant (data not shown). Luciferase assays demonstrated
that BLV promoter activity in infected D17 cells was about
10-fold greater than BLV promoter activity in non-
infected D17 cells (Fig. 3). CMV promoter activity
remained unchanged.
BLV Tax enhances BLV promoter expression but has no 
effect on the CMV promoter
To assess directly the effect of constitutive Tax expression
on the BLV promoter and CMV promoter, BLV Tax was
provided as a transgene to cells. As expected, Tax signifi-
cantly enhanced BLV promoter activity but had no effect
on CMV promoter activity (Fig. 4) inducing BLVp activity
about 48-fold in D17 cells and 4-fold in primary B cells.
Interestingly, we found that when BLV infected cells were
transduced with the Tax transgene, the resulting increase
in BLV promoter activity was a greater-than-additive
enhancement of BLV infection and Tax transgene (Table
1). This effect could likely be caused by Tax expressed
from the trangene upregulating expression of the entire
BLV provirus, including Tax. The effect on the CMV pro-
moter was not significant. Further, BLVp activity was
enhanced in cell lines FLK (2-fold) and BL3.1 (4-fold)
actively producing high-levels of BLV (Fig. 5).
BLV infection enhances BLVp activity but has no effect on  CMVp activity Figure 3
BLV infection enhances BLVp activity but has no effect on 
CMVp activity. D17 cells or D17 cells infected with and pro-
ductively expressing BLV (D17+BLV) were transduced with 
luciferase expression vectors. Relative light units (RLU) of 
luciferase activity driven by either the BLV promoter (BLVp) 
or CMV promoter (CMVp) of 1 × 106 stably trasduced cells 
was measured during a 10 s period. Bars represent the arith-
metic mean and variance of 10 experiments. **P < 0.001 
determined by t-test.
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BLV Tax expression significantly enhances BLVp activity but has no effect on CMVp activity Figure 4
BLV Tax expression significantly enhances BLVp activity but has no effect on CMVp activity. D17 cells and primary bovine B 
cells (D17; B cells), or D17 cells and primary bovine B cells stably transduced with a BLV Tax expression vector (D17+TAX; B 
cells+TAX), were assayed. Relative light units (RLU) of luciferase activity driven by either the BLV promoter (BLVp) or CMV 
promoter (CMVp) of 1 × 106 stably transduced cells were measured during a 10 s period. Bars represent the arithmetic mean 
and variance of 10 experiments. **P < 0.001 determined by t-test.
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Trichostatin A non-specifically enhances BLV promoter 
and CMV promoter Activity
The deacetylase inhibitor trichostatin A (TSA) has been
shown to be the most efficient activator of BLV expression
known to date [23]. To determine whether increased pro-
moter activity due to TSA was a generalized attribute
applicable to the CMVp as well, D17, FLK, and BL3.1 cells
possessing BLVp or CMVp driven luciferase expression
were treated with TSA. However, since CMVp activity was
already 50-fold greater than BLVp activity in D17 cells,
comparison of TSA induced promoter activities in a cell
line where BLV and CMV promoter activities were similar
would permit a more effective evaluation of TSA on the
two promoters. Further, TSA induced much less death
within the 48 h assay period in BL3.1 cells compared to
other cell lines tested (< 10%). Using BL3.1 with counts
adjusted for live cells, TSA treatment enhanced both BLVp
and CMVp activity by about 40-fold (Fig. 6) indicating
TSA was a non-specific promoter enhancer.
Discussion
Viral promoters are used in mammalian expression vec-
tors because they can have strong activity in a wide variety
of cells of differing tissues and species. Probably the most
employed is the CMV promoter because of its proven
high-level constitutive expression in a variety of mamma-
lian cell lines [24,25]. While constitutive transgene expres-
sion is suitable for certain research or gene therapy
applications, a strong regulated transgene expression is
preferable in many other applications [26]. The BLV pro-
moter, consisting of the U3 region of the LTR, is highly
dependant upon Tax for activation and transgene expres-
sion. In this study, we set out to determine the strength of
BLV promoter activity compared to the strength of the
CMV promoter to ascertain the utility of the BLV promoter
Table 1: Percent of Basal Luciferase Expression
Promoter D17+Tax D17+BLV D17+Tax+BLV
BLVp 115 ± 7 1226 ± 15 2038 ± 202
CMVp 96 ± 5 130 ± 23 118 ± 14
Tax trans-gene expression significantly enhances BLVp activity in cells producing high levels of BLV Figure 5
Tax trans-gene expression significantly enhances BLVp activity in cells producing high levels of BLV. FLK and BL3.1 cells, or FLK 
and BL3.1 cells stably transduced with a BLV Tax expression vector (FLK+TAX; BL3.1+TAX) were assayed. Relative light units 
(RLU) of luciferase activity driven by either the BLV promoter (BLVp) or CMV promoter (CMVp) of 1 × 106 stably transduced 
cells were measured during a 10 s period. Bars represent the arithmetic mean and variance of 10 experiments. *P < 0.05; **P < 
0.001 determined by t-test.
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for mammalian expression vectors. Information on the
BLV promoter describing the cis-acting elements and the
dependence upon Tax using reporter vectors in mamma-
lian cell lines has been published [13,27,28]. However, a
direct comparison of promoter strength of the BLV pro-
moter and the standard of mammalian expression vectors,
the CMV promoter, has not been performed.
Several attributes are important in developing a mamma-
lian expression vector. Probably the most important
attribute of a mammalian expression vector promoter is
its ability to accomplish high-level transcriptional activity
in a large variety of cell types of different tissues and spe-
cies. Our studies showed that the BLV promoter could
achieve similar high-level activity to the CMV promoter in
cells expressing BLV Tax or infected with BLV. This com-
paratively high BLV promoter activity was demonstrated
in D17 cells which we have found to be the highest
expresser of CMV promoter driven transgenes of all cell
lines tested in our laboratory. The CMV promoter activity
was still about 5-fold greater than BLV promoter activity
in the BLV infected D17 cells compared to the relatively
equal activity of the CMV promoter versus BLV promoter
in BLV infected FLK cells. However, FLK cells contain four
copies of the BLV provirus [29] whereas BLV infected D17
cells contain a single copy of the provirus (data not
shown). Thus there may be relatively greater expression of
Tax in FLK cells effecting greater activity of the BLV pro-
moter. Quantitative levels of Tax in BLV infected D17 or
FLK cells were not measured. In this study, we showed rel-
ative to the CMV promoter high levels of induced BLV
promoter activity in cell lines of canine osteosarcoma
(D17), fetal lamb kidney (FLK), bovine B-lymphosar-
coma (BL3.1), and bovine primary B cell origin. We also
have data (not shown) demonstrating high BLV promoter
driven transcriptional levels in cell lines derived from bat
lung (TB1Lu), monkey kidney (Vero), and human kidney
(HEK-293). Other researchers have also shown high BLV
promoter activity using reporter gene assays in cell lines of
various tissues derived from cow, dog, cat, mouse,
human, monkey, sheep, and hamster
[5,6,13,22,23,27,28]. Clearly the BLV promoter possesses
the significant trait of high-induced expression in a wide
variety of cell types.
A second important attribute of an inducible promoter
apart from high-induced expression is low basal expres-
sion. Researchers have reported barely detectable BLV
promoter Tax-independent activity through luciferase
assays of COS-1, C8, and KU-1 cell transient transfections
[28]. Our results using reporter vector stable D17 cell lines
showed low but definite BLV promoter basal activity. Oth-
ers measuring BLV promoter-driven luciferase activity in
transiently transfected D17 cells reported an above
background activity of the BLV promoter, but the basal
activity seemed much closer to background than we report
here [6,23]. The difference could be due to vectors
employed (the commercial retrovector we used had weak
promoter activity from the 5'LTR (data not shown) and
our vectors contained the WPRE), or that we used stable
cell lines versus transient transfections. Researchers using
B cell lines (Raji, Daudi, DG75, A20) also showed low,
but definite BLV promoter activity in transient and stable
transfected cells similar to our results using primary B cells
[6,13,27]. Nevertheless, in all of these studies Tax addi-
tion was able to induce expression ranging from 50 to
800-fold over basal expression. Our data showed Tax
enhanced BLV promoter activity to levels comparable to
the CMV promoter. A low but significant BLV promoter
Tax-independent activity is not surprising considering the
E boxes, CRE, GRE, NFkB and PU.1/Spi-B binding sites are
available for cellular transactivating factors (Fig. 1). In
fact, mutation studies of these cis-elements have demon-
strated significant decreases in basal level activity, as with
the mutation of the GRE site [30], significant increases in
basal level activity, as with the mutation of the CRE sites
[6], or either decrease or increase in basal activity, depend-
ing on the cell line assayed, as with mutations of the E box
[30]. Still, compared to CMV promoter activity, or Tax-
induced activity, BLV promoter basal activity is very low.
A third important attribute for an inducible promoter
would be a sensitive modulated response to a specific
Trichostatin A (TSA) enhances BLVp and CMVp activity Figure 6
Trichostatin A (TSA) enhances BLVp and CMVp activity. Rel-
ative light units (RLU) of luciferase activity driven by either 
the BLV promoter (BLVp) or CMV promoter (CMVp) of 1 × 
106 stably trasduced cells was measured during a 10 s period. 
BL3.1 cells were either non-treated or treated with 500 nM 
TSA for 48 h. Bars represent the arithmetic mean and vari-
ance of 10 experiments. **P < 0.001 determined by t-test.
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inducer. Enhancement of the BLV promoter can occur
independent of Tax by the addition of activating agents.
Phorbol esters, phytohemaglutinin, and lipopolysaccha-
rides have all been shown to enhance BLV promoter
expression [31]. However, all of these agents are non-spe-
cific activators and upregulate many promoters within the
cell [32]. The most efficient activator of BLV expression is
the deacetylase inhibitor, trichostatin A (TSA). Addition
of TSA to D17 cells enhanced luciferase expression driven
by the BLV promoter 11-fold over basal expression [23].
In BL3.1 cells, less variability occurred from TSA induced
cell death and basal BLVp and CMVp activity was rela-
tively the same. TSA upregulated activity of both BLV and
CMV promoters within BL3.1 by about 40-fold. In con-
trast, the BLV promoter was specific to Tax activation,
while CMV promoter expression was not affected by Tax.
For example in D17 cells, Tax specifically increased BLVp
activity 48-fold.
Nevertheless, the transactivating properties of BLV Tax are
not limited to activation of the BLV promoter. Tax has
been shown to upregulate Bcl-2 and increase nuclear
NFkB activity [17]. Tax expression induces immortaliza-
tion of primary rat embryo fibroblasts and causes
cytokine-independent B cell growth [17,33]. These "side
effects" of Tax may deter the use of BLV promoter for
mammalian expression vectors. However, studies have
demonstrated that the BLV promoter transactivation and
immortalization activities of wild-type Tax can be dissoci-
ated by mutations within specific regions of the protein
[9]. In fact, phosphorylation of Tax serines 106 and 293
are required for in vitro cell transformation but not BLV
LTR transactivation [34]. Tax transcriptional activity
requires an amino-terminal zinc finger and an internal
leucine-rich activation domain [9]. Phosphorylation-defi-
cient Tax mutants have been developed [33] and could be
used in place of wild-type Tax for BLV promoter transacti-
vation. Other mutations of Tax were shown to enhance
BLV promoter activity in 293T cells by 10-fold over wild-
type Tax [22]. However this mutant also transactivated the
cellular proto-oncogene c-fos. Clearly, there is great
potential to magnify the desirable traits of the BLV pro-
moter/Tax system for mammalian expression vectors and
minimize undesirable traits.
Conclusions
To determine whether the BLV promoter could be a useful
mammalian expression vector element, we compared its
activity with the CMV immediate early promoter in dog
osteosarcoma (D17), BLV-infected fetal lamb kidney
(FLK), BLV-infected bovine B-lymphosarcoma (BL3.1),
and primary bovine B-cells. Without concomitant Tax
expression from a transgene or BLV infection, the BLV pro-
moter activity was low compared to CMV promoter activ-
ity. In the presence of Tax or BLV expression, the BLV
promoter activity became equally as active as the CMV
promoter. The CMV promoter was not influenced by Tax
or BLV. Tax overexpressed as a transgene in BLV infected
cells resulted in BLV promoter expression greater than
CMV promoter expression. The deacetylase inhibitor, tri-
chostatin A was a potent upregulator of both BLV and
CMV promoters. Our results indicate the BLV promoter
has great potential use as an inducible promoter for mam-
malian expression vectors.
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